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Abstract
MP-MRI is a critical component in active surveillance (AS) of
prostate cancer (PCa) because of a high negative predictive
value for clinically significant tumours. This review illustrates
pitfalls ofMP-MRI and how to recognise and avoid them. The
anterior fibromuscular stroma and central zone are low signal
on T2W-MRI/apparent diffusion coefficient (ADC), resem-
bling PCa. Location, progressive enhancement and low signal
on b≥1000mm²/s echo-planar images (EPI) are differentiating
features. BPH can mimic PCa. Glandular BPH shows in-
creased T2W/ADC signal, cystic change and progressive en-
hancement; however, stromal BPH resembles transition zone
(TZ) PCa. A rounded morphology, low T2 signal capsule and
posterior/superior location favour stromal BPH. Acute/
chronic prostatitis mimics PCa at MP-MRI, with differen-
tiation mainly on clinical grounds. Visual analysis of
diffusion-weighted MRI must include EPI and appropriate
windowing of ADC. Quantitative ADC analysis is limited
by lack of standardization; the ADC ratio and ADC histo-
gram analysis are alternatives to mean values. DCE lacks
standardisation and has limited utility in the TZ, where
T2W/DWI are favoured. Targeted TRUS-guided biopsies
of MR-detected lesions are challenging. Lesions detected
on MP-MRI may not be perfectly targeted with TRUS and
this must be considered when faced with a suspicious le-
sion on MP-MRI and a negative targeted TRUS biopsy
histopathological result.
Keypoints
•Multi-parametricMRI plays a critical role in prostate cancer
active surveillance.
• Low T2W signal intensity structures appear dark on ADC,
potentially simulating cancer.
• Stromal BPH mimics cancer at DWI and DCE.
• Long b value trace EPI should be reviewed
• Targeted biopsy of MR-detected lesions using TRUS guid-
ance may be challenging.
Keywords Prostate cancer . Active surveillance of prostate
cancer . Multi-parametricMRI . Targeted biopsy .
Diffusion-weighted imaging
Introduction
Prostate cancer (PCa) is the most common cancer among males
in North America [1, 2] and the most common solid neoplasm
in Europe [3]. PCa is typically diagnosed with non-targeted
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patients with an elevated prostate serum antigen (PSA) level
and/or abnormal digital rectal examination (DRE). The man-
agement of a particular patient with PCa is multi-factorial and
patient specific due to the biological heterogeneity of PCa. Tra-
ditional treatment of PCa varies from radical prostatectomy
(RP) or radiotherapy (RT) to watchful waiting (delayed symp-
tomatic non-curative treatment of apparently localised PCa in
males who are not candidates for aggressive local therapy) [1,
3]. Active surveillance (AS) is defined as the expectant man-
agement (deferred immediate therapy) of PCa in carefully se-
lected males with localised disease considered to be at low risk
for progression [4]. AS differs from watchful waiting because
definitive treatment is used in patients managed with AS when
there is evidence that the patient is at an increased risk for
disease progression [4, 5]. AS has become the treatment of
choice for low-grade, low-volume tumours [6, 7] and is heavily
reliant on accurate detection of tumour, accurate estimate of
tumour volume and accurate Gleason grading of tumour [6, 7].
Non-targeted TRUS-guided biopsy typically obtains 6–12
core biopsies of the peripheral zone (PZ), which harbours ap-
proximately 70 % of cancers [1, 8]. The limitations of non-
targeted TRUS-guided biopsy are well known [8] with an esti-
mated 20 % false-negative rate [9–11]. Furthermore, non-
targeted TRUS-guided biopsymay yield unreliable information
regarding the volume, extent and aggressiveness of PCa; it is
has been reported that up to 30–45 % of patients are upgraded/
upstaged from their initial diagnosis at TRUS-guided needle
biopsy after RP [12]. Moreover, certain areas of the prostate
gland [i.e., the anterior gland, transition zone (TZ) and apex] are
known to be under-sampled or not sampled at all at routine non-
targeted TRUS-guided biopsy and are now increasingly being
recognised as areas that may contain clinically significant (CS)
tumours [13]. These limitations are of critical importance in
AS, where treatment decisions are based on risk stratification
and dependent on accurate Gleason grading of tumours [4].
Multi-parametric (MP) MRI [diffusion-weighted imaging
(DWI)+dynamic contrast enhancement (DCE) and/or MR spec-
troscopy] has become the reference standard for prostate imaging
endorsed by both the American College of Radiology (ACR)
and European Society of Uroradiology (ESUR) [14, 15]
(Table 1). Two recent meta-analyses concluded that MP-MRI
has a high negative predictive value for the detection of CS
cancers [16, 17], and it has been shown previously that MP-
MRI can estimate grade of PCa compared to histopathology
results with a reasonable degree of accuracy [18]. Due to the
ability ofMP-MRI to detect clinically significant (higher volume
Gleason score≥7) tumours with high degrees of accuracy, it has
become of tremendous value in AS [19]. Recent studies have
demonstrated that MP-MRI can help to determine eligibility for
AS [20] and potentially reclassify patients already enrolled in AS
before repeat biopsies [21]. In the UK, the National Institute for
Health and Care Excellence (NICE) guidelines currently man-
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MP-MRI be performed in patients while they are enrolled in AS
when there is concern about clinical or PSA changes [22].
A variety of interpretive and technical pitfalls may be en-
countered at MP-MRI of the prostate. A failure to recognise
and correct these errors in AS patients can result in suboptimal
care. False-positive diagnoses of areas of potential cancers at
MP-MRI create clinical uncertainty and often lead to multiple
unnecessary biopsies or in certain cases surgical management
of low-grade, low-volume disease. Moreover, a failure to rec-
ognise clinically significant cancers in males being considered
for or treated with AS could result in suboptimal patient out-
comes. The purpose of this review is to illustrate both inter-
pretive and technical pitfalls encountered at MP-MRI in the
active surveillance population and how to detect, correct and
avoid them.
Interpretive pitfalls
(1) Normal anatomic structures can mimic anterior and
TZ cancers
A detailed understanding of the normal zonal anatomy of
the prostate is essential for interpretation of prostate MRI. In
1981, McNeal [23] described the three distinct prostate zonal
regions: (1) the peripheral zone, (2) transition zone and (3)
central zone (CZ). The prostatic zonal anatomy is best
depicted at T2-weighted (W) MRI (Fig. 1). The PZ is hyper-
intense on T2W because of abundant glandular tissue, is lo-
cated at the periphery of the gland and harbours 70 % of PCa
[24] (Fig. 1). Previously, it was thought that the TZ [the site of
benign prostatic hyperplasia (BPH)] and the CZ (which sur-
rounds the ejaculatory ducts, is located mainly at the base of
the prostate, is posterior to the TZ and the urethra, and is
proximal to the verumontanum) could not be differentiated
at imaging and these areas were collectively referred to as
the central gland [25, 26]. The central gland in most adult
males consists of hypertrophied TZ that compresses the CZ
against the surgical capsule [25]. Currently, it is acknowl-
edged that the CZ can be identified separately from the TZ
in up to 4/5 of males and the CZ appears as a symmetric band
of homogeneously low signal intensity (SI) on T2WMRI and
apparent diffusion coefficient (ADC) maps best seen at the
prostate base [25], (Fig. 1).
Accurate identification of the CZ is critical as, in our expe-
rience, many false-positive interpretations of PCa occur when
mistaking the CZ for PCa. The CZ can be diagnosed by noting
its symmetry (particularly on coronal T2W images) and typi-
cal location adjacent to the ejaculatory ducts [25, 26]. Func-
tional imaging techniques also aid in the differentiation of CZ
Fig. 1 A 54-year-old male with low volume Gleason score 3+3=6 PCa
at TRUS-guided biopsy in the right middle peripheral zone (PZ). MP-
MRI was performed because of rising PSA to exclude clinically signifi-
cant (CS) tumour. Axial (a) and coronal (b) T2-weighted (T2W) turbo
spin echo (TSE) images demonstrate bilateral foci of low T2 signal inten-
sity (SI) at the prostate base (dotted arrows) adjacent to the insertion of
the vas deferens (not shown). Axial apparent diffusion coefficient (ADC)
map (c) at the same level demonstrates corresponding low SI (white
arrows). These areas were described as suspicious and repeat targeted
TRUS-guided biopsy was suggested. A repeat biopsy with multiple cores
through both areas yielded only normal prostatic tissue. A repeat MRI
performed 2 years later demonstrates similar findings on the T2W (d) and
ADC map (e), which represent the normal central zone. Corresponding
b1000 mm²/s trace echo-planar image (EPI) does not show concordant
areas of increased SI (white arrows in f) and there is benign progressive
enhancement on dynamic contrast-enhanced (DCE) imaging (g)
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from PCa. In the normal CZ, low SI on ADC is due to inher-
ently low T2 SI not true restricted diffusion (BT2 black hole
effect^); see Technical Pitfall 2. In the normal CZ, there is no
true diffusion restriction; therefore, there should be no in-
creased SI on long (b≥1000 mm²/s) EPI (Figs. 1 and 2). The
enhancement pattern of the CZ at DCE has not, to our knowl-
edge, been described; however, in our experience, a progres-
sive type 1 enhancement is typical of the CZ (Fig. 1). CZ PCas
are aggressive [26–28], but account for less than 5 % of PCa
[26]. An asymmetry of the central zone should raise suspicion
for a possible tumour [25]; however, it is more common to
observe a slight asymmetry in the thickness of the CZ because
of the orientation of the prostate gland and the plane of imag-
ing (Fig. 2). To diagnose the rare CZ PCa, asymmetry at T2W
should be confirmed in multiple planes and corresponding
functional imaging findings such as increased signal intensity
on long b value trace EPIs and/or suspicious contrast kinetics
at DCE are helpful, as these latter findings are not expected in
the normal CZ (Fig. 2). Ultimately targeted biopsy or MRI
follow-up may be necessary for suspicious areas in the CZ.
The anterior fibromuscular stroma (AFMS) is a normal
structure at the extreme anterior midline of the prostate gland,
which is inseparable from the surrounding normal prostatic
stroma [25, 29]. The AFMS contains no glandular tissue and
is composed of widely spaced smooth muscle cells. It appears
homogeneously hypointense on T2W MRI and because of
this inherent low T2W SI will appear as low SI on ADCmaps.
Differentiation of the AFMS from anterior cancer is
established by noting the midline location, well-defined mar-
gins, lack of true diffusion restriction (absence of high SI on
b≥1000 mm²/s EPI) and a benign progressive type 1 enhance-
ment pattern at DCE (Fig. 3) [25, 30]. PCa arising in the
extreme anterior prostate can resemble the AFMS and inmany
cases anterior tumors can extend up to or invade the AFMS.
Both lesions are low SI on T2W; however, anterior PCa is
more lenticular or polygonal in shape, has ill-defined or
smudged borders, and the bulk of the lesion tends to be off
midline (Fig. 4) [31]. The use of functional imaging sequences
is contributory (Fig. 4) [30]. DWI increases accuracy for de-
tection of anterior cancers because anterior tumours will be of
low SI on ADC because of true restricted diffusion, demon-
strating increased SI on trace b≥1000 mm²/s EPI [32]. The
utility of DCE in the TZ and anterior prostate is controversial
[33]; however, authors have demonstrated more aggressive
enhancement patterns in anterior PCa [34–37]. In our experi-
ence, DCE can be beneficial to discriminate anterior PCa from
AFMS; however, overlap with stromal BPH limits its utility in
the TZ (discussed later) [35].
(2) Post-biopsy haemorrhage can mimic PZ PCa on
T2WMRI
Detection of PCa on T2W is predicated on the ability to
discriminate low T2 SI tumour from the normal adjacent high
T2 SI PZ [15, 38–40]. The glandular tissue of the PZ contains
high concentrations of citrate, which is a natural anti-
coagulant; therefore, post-procedural haemorrhage is com-
monly observed at MRI after prostate biopsies and can persist
for up to 4 months after the procedure [41]. Areas of post-
biopsy haemorrhage are characteristically hypointense on
T2W MRI in up to 80 % of cases and can mimic PCa [41]
(Fig. 5). This pitfall is easily avoided by cross-referencing
T2W to pre-contrast T1W imaging because areas of haemor-
rhage will also be characteristically hyperintense on T1W
(Fig. 5).
Many institutions continue to defer prostate MRI studies
until 3–8 weeks have passed after the biopsy to reduce the
amount of post-biopsy haemorrhage and facilitate interpreta-
tion. With the advent of functional imaging sequences post-
biopsy haemorrhage is, in our experience, much less problem-
atic. Areas of tumour have been shown to be reliably differ-
entiated from haemorrhage using DWI, and DCE analysis can
be interpreted through image subtraction [42] (Fig. 5). More-
over, because PCa contains less citrate than the normal PZ,
Fig. 2 A 51-year-old patient with low-volume Gleason score 3+3=6 at
non-targeted TRUS-guided biopsy. MP-MRI was performed at onset of
active surveillance (AS) to exclude higher grade tumour. Axial (a) and
sagittal (b) T2W images demonstrate an ill-defined ovoid lesion of low
T2 SI at the junction of the right PZ and transition zone (TZ) (dottedwhite
arrow) along the course of the surgical capsule. Axial ADC map image
(c) at the same level demonstrates corresponding low SI (white arrow).
This area was considered suspicious for tumour. Targeted TRUS biopsy
was performed and yielded only normal prostate tissue. The area did not
change on follow-up MP-MRI and represents asymmetry of the normal
central zone. In retrospect, corresponding b1000 mm²/s trace EPI (d) did
not show increased signal (white arrow) in this area
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areas that are devoid of haemorrhage in the PZ after biopsy
may actually highlight the tumour on T1W imaging
(Bhaemorrhage exclusion sign^) [42]. This imaging finding
has recently been shown to have >95 % positive predictive
value for tumour localisation when combined with
characteristic imaging findings at T2W MRI [42].
(3) Benign prostatic hyperplasia (BPH) resembles TZ
PCa
BPH is extremely common in the TZ and its prevalence
increases with age. BPH can be nodular and TZ nodules are
commonly encountered at MP-MRI [35], and nodular BPH
may mimic TZ PCa [25]. Nodular BPH is categorised into
three main subtypes: glandular, stromal and mixed.
Glandular BPH is characterised histologically by hyperpla-
sia of glandular tissue with papillary buds, infoldings and
cysts. Glandular BPH is readily differentiated from TZ PCa
at MP-MRI [35] and typical features include a well-
circumscribed, sharply demarcated and rounded shape, a
continuous low T2W SI rim, increased T2W SI often with
cystic change, low SI on long≥1000 mm²/s b value EPI, BT2
shine-through^ on ADC maps and benign/progressive/type I
contrast kinetics with a low transfer constant on DCE (Fig. 6)
[25, 35].
The presence of increased smooth muscle, lymphocytes
and ducts (not associated with prostatitis) and reduced elastic
tissue characterises stromal BPH at histopathology. Stromal
BPH nodules can be difficult to differentiate from TZ PCa
[35] (Figs. 6 and 7). Stromal BPH is typically of low T2W
SI, similar to TZ PCa. Stromal BPH is also of low signal
intensity on ADC maps because of both inherently low T2W
SI and true restricted diffusion (due to compact cellularity)
and may or may not have increased SI on long
b≥1000mm²/s trace EPI. Furthermore, ADC values in stromal
BPH are low and overlap with TZ PCa [25, 35]. DCE is
limited to differentiate stromal BPH from TZ PCa, because
enhancement patterns of stromal BPH overlap with TZ PCa
[33–35]. Previous authors have reported lower ADC and
higher K-trans values in TZ PCa compared to stromal BPH,
Fig. 3 A 54-year-old patient with elevated and rising PSA. Axial T2W
TSE (a) demonstrates a low SI focus in the anterior midline (dotted
arrow) with corresponding low SI (white arrow) on the axial ADC map
(b). This area was reported as suspicious for tumour. Repeat non-targeted
biopsies of the PZ revealed Gleason score 3+4=7 tumour in the right PZ
(not shown) and the patient underwent radical prostatectomy (RP). The
structure highlighted onMRI is the normal anterior fibromuscular stroma
(AFMS); note: characteristic midline anterior location on axial T2 (a) and
benign progressive enhancement onDCE (c). Also note that low SI on the
ADC (b) map is due to inherently low T2 SI rather than restricted
diffusion; there is a lack of increased SI on trace b1000 mm²/s EPI (d).
Whole-mount histopathology image of the RP specimen (e) demonstrates
the AFMS (black arrow), which is predominantly composed of smooth
muscle that blends with the overlying prostate stroma
Fig. 4 A 50-year-old patient with rising PSA and a typical anterior
tumour involving the right side of the gland. Axial T2W TSE (a)
demonstrates an amorphous, off midline, lenticular-shaped, ill-defined
low T2 SI region (white arrow) with low SI (black arrow) on the ADC
(b) map due to restricted diffusion (note increased SI on trace b1000mm²/
s EPI (white arrow in c) and type III contrast curve kinetics onDCE (d). A
targeted TRUS biopsy was performed and confirmed Gleason score 4+
3=7 tumour anteriorly. Corresponding microscopic image from TRUS
biopsy (e) demonstrates Gleason pattern 4 tumour
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but substantial overlaps exist (Figs. 6 and 7) [35]. Other dif-
ferentiating features that are more suggestive of stromal BPH
include well-defined sharply demarcated margins, a continu-
ous low T2W SI rim and a rounded shape (Figs. 6 and 7) [31,
33].
At histopathology and MP-MRI, it is more common to
identify a TZ BPH nodule with features of both glandular
and stromal BPH. Typically one pattern (glandular or stromal)
will predominate; however, features of both types of BPH can
be seen within the same nodule, which can further complicate
the diagnosis. In cases of mixed BPH, a combination of im-
aging features of glandular and stromal BPH are encountered
[31]. Usually, the presence of increased T2W SI and cystic
change (from glandular BPH) within a lesion are reassuring
findings of BPH (Fig. 7) since these findings are rarely en-
countered in PCa.
Chesnais et al. previously demonstrated that the majority of
TZ cancers involve the anterior and apical third of the gland
[43]. At histopathology, Bouye et al. previously demonstrated
that anterior tumours tend to grow anteriorly and invade the
anterior fibromuscular stroma but rarely extend to the posteri-
or PZ [44]. It should be noted that in some instances, when
there is uncertainty at MP-MRI regarding the diagnosis of TZ
PCa versus stromal BPH due to overlap in imaging features, a
targeted biopsy or follow-up MP-MRI may be suggested
(Fig. 6).
(4) Acute and chronic prostatitis mimics PCa
Acute bacterial prostatitis (ABP) is commonly encountered
in clinical practice and often managed conservatively without
imaging or surgical intervention [38]. When patients with
ABP are imaged in the acute setting, prostatitis can mimic
PCa at MP-MRI, demonstrating low SI on T2WI, restricted
diffusion [45] and enhancement patterns that overlap with
PCa [25] (Fig. 8). Although PCa has been reported to demon-
strate more well-defined borders and nodular appearance
compared to prostatitis and lower ADC values [45, 46], aside
from the presence of abscess formation in prostatitis, differen-
tiation is mainly based on clinical grounds.
Fig. 5 A 58-year-old male patient with Gleason score 3+3=6 tumour
imaged with MP-MRI because of rising PSA. On axial T2W TSE (a)
there is a low SI focus in the left mid PZ (white arrow), which could
represent peripheral zone cancer. Corresponding axial T1W TSE (b)
demonstrates increased T1 SI (black arrow) in keeping with post-
biopsy haemorrhage. Axial ADC map (c) does not reveal the lesion
(black arrow), which was readily diagnosed as post-biopsy haemorrhage
Fig. 6 A 47-year-old patient post-total colectomy for ulcerative colitis
and elevated PSA. MP-MRI was performed to evaluate for potential
tumour and to plan a biopsy. Axial T2W TSE (a) image demonstrates
enlargement of the central gland (TZ) consistent with BPH. There is a
well-circumscribed, round, mixed but predominantly increased T2W SI
nodule with internal cystic change (white arrow) and a predominantly
homogeneously low T2 SI nodule at the junction of the right middle PZ
and central gland (dotted arrow). The larger nodule demonstrates T2
shine-through on the ADC map (black arrow in b) and is characteristic
of glandular BPH. The other nodule demonstrates restricted diffusion
(thick black arrow in b) and type III kinetics at DCE (c). A diagnosis of
prostate cancer was suggested. Targeted biopsy revealed normal prostatic
tissue and stromal BPH. Follow-up MRI (not shown) demonstrated no
change and the PSAwas stable. In retrospect, the nodule is round, well-
circumscribed and demonstrates a complete low T2 SI rim (a), findings
that are more in keeping with stromal BPH rather than cancer
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Granulomatous prostatitis (GP) is a benign inflamma-
tory entity that may also be indistinguishable from PCa
at MP-MRI, demonstrating low SI on T2W, restricted
diffusion and suspicious enhancement at DCE [47].
Moreover, granulomatous prostatitis can involve the
periprostatic fat or seminal vesicles, mimicking
extraprostatic spread of PCa (Fig. 9). With the correct
clinical history [e.g., previous bacille Calmette-Guerin
therapy for bladder cancer, tuberculous prostatitis or
previous intervention such as transurethral resection of
the prostate (TURP)], granulomatous prostatitis may be
favoured over PCa [25]; however, histological confirma-
tion is often required [47].
In the chronic setting, areas of prostatitis can mimic PCa
because they will demonstrate low T2W SI [48]. Functional
imaging techniques can be useful to differentiate areas of
chronic prostatitis from cancer (Fig. 10) but there is overlap
in imaging features [49, 50] and targeted biopsy or MP-MRI
Fig. 7 A 58-year-old patient with low-volume, low Gleason score 3+3=
6 tumour in the right mid-peripheral zone undergoing MRI prior to repeat
biopsy because of rising PSA. Axial T2W TSE (a) image demonstrates a
low T2 SI nodule in the left TZ (thick white arrow). The nodule is
predominantly homogeneously of low T2W SI but demonstrates a
small focus of cystic change anteriorly (arrowhead). Note that the
nodule is round and demonstrates a continuous low T2W SI rim (thin
white arrow). The nodule demonstrates restricted diffusion, increased SI
on trace b1000mm²/s EPI (b) and low SI on the ADCmap (c) (thick white
arrows). Note that cystic change demonstrates T2 shine-through
(arrowhead). Imaging findings are characteristic of a mixed but
predominantly stromal BPH nodule
Fig. 8 Acute prostatitis in a 46-
year-old patient with elevated
PSA. Axial T2W TSE (a)
demonstrates an amorphous area
of low T2 SI (dotted arrow) in the
left middle PZ with
corresponding low SI on ADC
map (black arrow in b) due to
restricted diffusion, note
increased SI on trace b1000 mm²/
s EPI (white arrow in c). There is
an indeterminate type II contrast
curve (plateau kinetics) on DCE
in (d). A differential diagnosis of
prostatitis or cancer was provided,
and biopsy or follow-up was
suggested. The patient had typical
findings of acute bacterial
prostatitis clinically and was
treated with antibiotics with
normalisation of PSA post
therapy
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follow-up of the suspicion region may be considered depend-
ing on the level of suspicion for tumour [47].
(5) Ductal variant adenocarcinoma may be occult on
T2W MRI
PCa is divided into the most common acinar adenocarcino-
ma and less common non-acinar subtypes. Ductal adenocar-
cinoma (DCa) is an aggressive variant of PCa and is the most
common of the non-acinar subtypes [51] with a reported inci-
dence of 0.5–6 % [52]. DCa is associated with higher rates of
positive surgical margins, extraprostatic extension, vascular
invasion, seminal vesicle invasion and metastases [53, 54].
A diagnosis of DCa at needle biopsy requires definitive ther-
apy and is considered an absolute contraindication for AS [55,
56]. Schieda et al. recently demonstrated that DCa is of in-
creased SI on T2WMRI, which can render the tumour occult
[39]; however, the same authors demonstrated that DCa re-
sembles Gleason score≥7 or higher tumour on DWI and DCE
[57]. Therefore, in a lesion with aggressive imaging findings
on DWI/DCE and paradoxical increased T2WSI, DCa should
be considered [57] (Fig. 11).
Fig. 9 A 64-year-old patient with rising PSA and history of recurrent
urothelial cell carcinoma of the urinary bladder treated with intra-vesical
BCG therapy. Axial T2W image (a) demonstrates a large mass infiltrating
throughout the right prostate (black arrow) and breaching the prostate
capsule laterally (arrowhead) consistent with extra-prostatic spread.
Axial b1000 mm²/s (b) and ADC map (c) demonstrate marked
restricted diffusion (white arrows) and axial image from DCE shows
marked early mass-like hyper-enhancement (type III curve was depicted
and is not shown). TRUS biopsy was performed and histology was
compatible with diffuse granulomatous prostatitis
Fig. 10 A 64-year-old patient with Gleason score 3+3=6 in <5% of one
core in the left middle PZ underwent MRI prior to enrolment into active
surveillance. Axial T2W TSE image (a) demonstrates a low T2 SI focus
in the left PZ (dotted arrow) with low SI on ADC (black arrow in b).
Based on these findings a diagnosis of potential higher grade tumour was
suggested and a repeat biopsy was performed. Saturation biopsies
through the left mid PZ revealed only normal prostatic tissue and areas
of chronic prostatitis. In retrospect, trace b1000 mm²/s EPI demonstrates
low SI (white arrow in c), which indicates that there is no restricted
diffusion in this area. Similarly, there is a benign progressive type I
enhancement curve on DCE (d), which further argues against a higher
grade tumour. Corresponding histopathology slide (e) demonstrates areas
of chronic inflammation
456 Insights Imaging (2015) 6:449–463
Technical pitfalls
(1) T2W motion correction with radial acquisition ob-
scures some PCa
As discussed, detection of tumour in the PZ on T2W
MRI is based on differentiation of low T2W SI tumour
from the high T2W glandular tissue [15, 38–40]. In the
TZ, T2W imaging is now recognised as the most impor-
tant pulse sequence for detection of PCa because of over-
lap between TZ cancer and stromal BPH on functional
imaging (see Interpretive pitfalls, stromal BPH) [58].
T2W imaging is typically performed using turbo/fast
spin-echo techniques [39]. Motion correction with radial
acquisition (BLADE, Siemens Healthcare, Malvern, PA,
USA; PROPELLER, General Electric Healthcare, Mil-
waukee, WI, USA) sequences are popular for pelvic im-
aging because they correct for in-plane rotation and trans-
lational artefacts and have been shown to result in im-
proved overall image quality when compared to conven-
tional spin echo [59, 60]. A disadvantage of these se-
quences is decreased image contrast compared to conven-
tional spin echo [59]. Recently, Rosenkrantz et al. dem-
onstrated that a minority of PCa foci may be obscured at
T2W MRI when BLADE/PROPELLER is used compared
to conventional spin echo [61] (Fig. 12).
Fig. 11 A 59-year-old patient with Gleason 3+4=7 cancer in the left
middle PZ on TRUS biopsy underwent MP-MRI for staging. Axial
T2W TSE image shows a subtle lesion in the left middle PZ (white
arrow in b) with type III kinetics on DCE (b) and profound restricted
diffusion on ADC map (white arrow in c). Typically with conventional
acinar adenocarcinoma T2W signal intensity mirrors findings on ADC
map, the discordant findings with only minimally decreased T2W signal
and profound restricted diffusion can be seen in ductal variant
adenocarcinoma. Final histopathology after RP was Gleason score 4+
4=8 tumour with dominant ductal component
Fig. 12 A 63-year-old patient with elevated PSA and previously
negative non-targeted TRUS-guided biopsy with persistent clinical sus-
picion of prostate cancer underwent MP-MRI in two separate sessions
within 3 months demonstrating the loss of contrast with BLADE/
PROPELLER imaging. Axial T2W BLADE a, b1000 mm²/s EPI b and
ADC map c demonstrate a suspicious focus of restricted diffusion in the
left middle anterior horn of the PZ (white arrows), which is not visible on
axial T2W BLADE (black arrow in a). Repeat examination performed
using T2W FSE (d) reveals a T2 hypointense nodule in the same location
(black arrow in d) with persistent restricted diffusion (white arrows in e
and f)
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(2) Visual/quantitative analysis of DWI for tumour
detection/grading is complex
DWI improves the detection of cancer foci in the PZ and
TZ, and ADC values derived from DWI have been repeatedly
shown to inversely correlate with Gleason grade of PCa [18,
38]. DWI is the single best imaging test for analysis of the PZ
and is used in conjunction with T2W MRI for evaluation of
TZ lesions [58, 62]. The visual analysis of DWI must include
assessment of trace EPI and should not rely solely upon re-
view of the derived apparent diffusion coefficient (ADC)map.
Structures that are inherently of low T2W SI will appear dark
on the ADC map because of an inherently low T2W SI (T2
Bblack-hole^ effect) and not from true restricted diffusion
(Figs. 1 and 2). Review of trace EPI is critical to avoid this
common pitfall because these structures will not appear bright
on long (b≥1000 mm²/s) EPI (Figs. 1 and 2). Conversely, PCa
(and as discussed some stromal BPH nodules) is of low SI on
ADC and will appear bright on the long (b≥1000 mm²/s) EPI
(Figs. 3, 6 and 7). The use of longer b values (b≥1000 mm²/s)
facilitates the detection of cancer foci compared to the benign
prostatic tissues [63, 64]. Visual analysis of ADC may be
further limited by automatic display settings and can result
in the failure to detect PCa or an underestimation of tumour
grade if not displayed properly (Fig. 13). A previous study
demonstrated that by using a window width=1.650 and lev-
el=1.675×10–6 mm²/s for display of ADC, higher grade tu-
mours were more likely to appear dark (Fig. 13) [65].
It has been demonstrated repeatedly that ADC values
inversely correlate to PCa grade [18]. The use of ADC
values across MR systems is problematic because of dif-
ferences related to magnet strength, vendor system and
selection of differing b values [57]. Furthermore, a variety
of methods to quantify ADC have been described includ-
ing single region of interest measurement versus whole
lesion analysis and mean, median and complex histogram
analysis of ADC. Application of quantitative ADC thresh-
olds may be limited by these factors. A recent study dem-
onstrated that the use of an ADC ratio (normalised to ad-
jacent normal PZ) provided a better inter-scanner compar-
ison than the absolute ADC value [57]. Mean ADC values
may also be limited due to the variable composition of
prostate cancers and when comparing intermediate prostate
cancers (Gleason score 3+4=7 vs. 4+3=7) [66] and stud-
ies have demonstrated that the use of the low percentile
ADC may be a better reflector of the Gleason score [67,
68]. Regardless of the method used, due to differences
across systems, at present, we suggest that the use of quan-
titative ADC in clinical practice should be applied careful-
ly, derived and validated on an institutional basis.
Fig. 13 A 55-year-old patient with low-volume Gleason score 3+3=6
tumour at TRUS biopsy in the left apical PZ underwent MRI prior to
consideration for potential AS. Axial T2W TSE image (a) demonstrates a
low T2 SI focus in the left apical PZ (white arrow). Axial ADC map
displayed with automatic windowing/levelling shows minimal
decreased SI (black arrow in b). These findings could be considered
typical for a 3+3=6 cancer. With modified display of the ADC map
using previously validated settings (width=1.650 and level=1.675×10–
6 mm²/s) the nodule (black arrow in c) is noted to be of lower SI than
initially displayed in (b). Using quantitative data, the ADC value obtained
within the tumour (d) was 1.462×10−3 mm²/s, which would also be
considered to be of low (Gleason score 6) grade using previously
reported thresholds. Comparing ADC values across systems is
challenging due to a lack of standardization, and an ADC ratio has been
previously proposed as a better metric to compare ADC. An ADC value
from the contralateral normal PZ obtained at the same level was 2.000×
10−3 mm²/s, which yields an ADC ratio of 0.73, which would be com-
patible with a Gleason score≥7 tumour based on previously published
thresholds. Corresponding DCE image (e) from the same level demon-
strated a focal enhancing nodule with a type III contrast curve. Based on
the imaging findings, a repeat TRUS-guided biopsy was performed,
which demonstrated Gleason pattern 4 in the left apical PZ
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(3) DCE lacks standardisation and is limited in the TZ
DCE improves the detection of PCa and DCE param-
eters correlate with PCa grade [69–71]. Currently, there
is no established interpretation criteria for DCE analysis
which varies from simple visual analysis to semi-
quantitative analysis to full quantitative pharmacokinetic
modelling [72]. A recent study demonstrated that DCE
is underutilised in clinical practice compared to DWI
and that semi-quantitative and quantitative analyses
were not commonly used [72]. In the revised PI-
RADS v2.0 guidelines, DCE analysis has been modified
from semi-quantitative curve analysis to a simple visual
analysis [58].
Moreover, DCE is very limited for the detection and grad-
ing of cancers in the transition zone because of significant
overlap with stromal BPH (Fig. 7). Analysis of potential tu-
mour foci in the transition zone should preferentially favour
T2W and DWI over DCE. It is currently recognised that the
utility of DCE in clinical practice is mainly as a confirmatory
sequence for PZ lesions [58]; however, further studies are
required to determine the value of DCE in PCa.
(4) Targeted biopsy of MR-detected lesions using TRUS-
guidance is challenging
MP-MRI for PCa has transformed practice, but has created
new challenges. Obtaining accurate histological correlation
Fig. 14 A 59-year-old patient with low-volume Gleason score 3+3=6 at
non-targeted TRUS biopsy underwent MP-MRI to exclude clinically
significant cancer after an increase in PSA. Axial T2W TSE image (a)
demonstrates a low T2 SI focus in the left PZ (open white arrow) with
restricted diffusion; note increased SI on trace b1000 mm²/s EPI and low
SI onADC (white arrows in b and c, respectively). Based on theMRI and
clinical findings a diagnosis of potential higher grade tumour was
suggested and a targeted repeat biopsy was performed. At time of
repeat biopsy, which used cognitive registration of MP-MRI and TRUS
data, no lesion could be identified at TRUS. Only one core biopsy
through the left medial mid peripheral zone sextant was performed.
Microscopic image from repeat TRUS-guided biopsy (d) demonstrates
Gleason pattern 3 tumour. Continued in Fig. 14
Fig. 15 Although only low-volume Gleason score 3+3=6 was again
noted at repeat TRUS biopsy (Fig. 13), a follow-up MP-MRI was
performed 3 months later because of interval doubling of PSA to re-
evaluate for a focus of higher grade cancer. Axial T2W TSE image (a)
demonstrates that the small low T2 SI focus in the left PZ has grown
substantially (open white arrow) with bulging and nodular extension into
the peri-prostatic fat (arrowhead), which was reported as representing
extra-prostatic extension. The lesion again demonstrates restricted
diffusion; note increased SI on trace b1000 mm²/s EPI and low SI on
ADC (white arrows in b and c, respectively) and demonstrated an
aggressive type III contrast curve on DCE (d). In the interval, a
malignant-appearing lymph node developed along the left pelvic
sidewall (e). Based on these findings a diagnosis of high-grade tumour
with extra-prostatic extension and metastatic adenopathy was provided.
The patient underwent RP based on the imaging findings, he declined a
repeat biopsy because of previous urosepsis related to prior TRUS biopsy.
Correspondingmicroscopic images (f and g) demonstrate Gleason pattern
4 tumour (white arrows in f) and extra-prostatic extension of tumour
(open arrow), which is beyond the prostate capsule (black line) and into
the peri-prostatic fat (g)
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from lesions detected at MP-MRI may be challenging. MRI
guided biopsy is accurate; however, this technique is limited
by cost, availability of and access to MRI, prolonged proce-
dure times and patient discomfort [8]. The use of TRUS guid-
ance for biopsy of MP-MRI-detected lesions is currently a
preferred option.
Using existing technology, so-called cognitive registration
(CR) is performed. CR requires the TRUS operator to mentally
integrate MP-MRI with real-time TRUS, identify suspicious
MR lesions and, with TRUS guidance, target those lesions for
biopsy. Published data regarding the applicability of CR are
limited to institutional series and are highly subject to operator
experience [8]. TRUS may be limited for the detection of tu-
mours in the PZ and is also limited for assessment of the TZ and
the anterior gland in many patients with enlarged glands due to
poor ultrasound beam penetration. A failure to recognise the
limitations of TRUSwhen performingCR biopsies can result in
a failure to adequately sample suspicious areas onMP-MRI and
ultimately result in delayed diagnosis and therapy for clinically
significant PCa (Figs. 14 and 15). In our experience, cognitive-
ly registered TRUS biopsy of MP-MRI-detected lesions can be
successful, provided that the TRUS operator recognises the
limitations of TRUS for demonstrating a corresponding lesion
to that seen on MP-MRI. It is not uncommon for a lesion
detected in the PZ or TZ on mp-MRI to be sonographically
occult on TRUS and, in these instances, by oversampling the
corresponding location using anatomic landmarks, the diagnos-
tic yield can be significantly improved (Fig. 16).
The use of Fusion software (which automatically integrates
MP-MRI data with real-time 3D TRUS images) provides an
alternative to cognitive registration [8]. Fusion software is not
without its own limitations including mainly errors in fusion
that relate to the spatial deformation of the prostate at TRUS
compared to mp-MRI [8]. Moreover, this technology is ex-
pensive and at the moment is available in a few specialised
centres, although availability is increasing. Studies comparing
cognitively registered targeted TRUS biopsy to software fused
targeted TRUS biopsy are lacking and have shown mixed
results. While several studies have shown no difference be-
tween CR and Fusion software [73, 74], other studies have
shown an improvement in the detection rate of cancer using
fusion software systems [75, 76].
It is critical to emphasise that when a targeted TRUS-guided
biopsy performed for a suspicious lesion detected onMP-MRI
(using either cognitive registration or fusion software) is neg-
ative, the MP-MRI should be reviewed in the context of the
biopsy results and other clinical factors in order to consider the
possibility of an erroneous targeted biopsy. In these instances,
repeat MRI or targeted biopsies can be contemplated.
Conclusion
In conclusion, MP-MRI has become a critical component
for patients being considered for or enrolled in active
surveillance protocols for the management of low-grade
and low-volume prostate cancers. MP-MRI is a proven
imaging modality that can detect clinically significant foci
of prostate cancer with high degrees of accuracy; the high
negative predictive value of MP-MRI is particularly well
suited for the AS of PCa. A number of pitfalls, both in-
terpretive and technical, may be encountered at MP-MRI
of the prostate and a failure to recognise these pitfalls in
the AS population can result in suboptimal patient care.
Targeted biopsies of MP-MR-detected lesions poses a new
challenge and opportunity in clinical practice. The limita-
tions of TRUS-guidance for lesion detection during
targeted biopsies should be acknowledged in order to im-
prove the diagnostic yield of targeted biopsies. A thor-
ough understanding of these MP-MRI pitfalls is important
for the MR practitioner involved in the management of
prostate cancer.
Fig. 16 A 63-year-old patient underwentMP-MRI prior to routine repeat
biopsies as part of his active surveillance protocol. Axial T2W TSE (a),
axial ADC map (b) and semi-quantitative contrast curve derived from
DCE (c) demonstrate a focal low T2W SI lesion (black arrow) with
restricted diffusion (white arrow) and type III kinetics in the left middle
peripheral zone. At repeat targeted biopsy using cognitive registration, no
corresponding lesion could be identified. With a priori knowledge of the
location of the lesion at MP-MRI, the TRUS operator performed three
core needle biopsies through the left middle lateral and two core needle
biopsies through the left middle medial PZ sextants. Results after targeted
biopsies were Gleason 4+3=7 tumour with two out of three core biopsies
in the left middle lateral PZ sextant
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